SBHMY News and Press, Sino Biopharmaceutical Ltd ADR From 06/05/22

Vivo Capital, a US-China healthcare investor, held its first closing of a yuan-denominated private equity fund at $600 million, with a target of bringing the fund to $1.5 billion. SciNeuro Pharma, a Shanghai CNS company, acquired global rights to Lp-PLA2 inhibitors for neurodegenerati...

Fosun Pharma acquired China rights to a novel broad cancer immunotherapy candidate from VerImmune of Baltimore in a $125 million agreement. Oncotelic Therapeutics, a South San Francisco company, formed a Hong Kong JV with Dragon Overseas Capital to develop TGF-β therapeutics. ...

Leading biotech company Novavax (NVAX) has received temporary approvals for the use of its COVID-19 vaccine from several countries and has filed for emergency use authorization from the U.S. FDA. However, with several high-efficacy vaccines already available in the market, will NVAX be able t...

Ginkgo Bioworks (DNA) went public last September through an SPAC deal with Soaring Eagle Acquisition Corporation, a blank-check company led by former MGM CEO Harry Sloan. However, the stock has nosedived in price since its market debut. In addition, given an ongoing investigation into the com...

Biotech company 22nd Century Group (XXII) received FDA approval to market its VLN Group cigarettes as modified risk tobacco products on December 23, 2021.The cigarettes contain 95% less nicotine than traditional cigarettes. But should one invest in XXII now with its negative profit margins an...

Biotech company Cassava Sciences (SAVA) is known for its Alzheimer’s drug, currently in phase three clinical trials. The stock has gained triple digits so far this year. However, with the SEC investigating claims that the company allegedly manipulated its prior clinical trial results, ...

Shares of the Ireland-based biopharmaceutical company Jazz Pharmaceuticals (JAZZ) have declined 26.7% over the past three months. While the company’s recent drug approvals and collaborations could boost its price, its mixed financials and uncertain growth potential are concerning. So, ...

Corvus Pharmaceuticals (CRVS) has been making headway on several developments in the immuno-oncology therapies space, which sent its shares soaring to their 52-week high of $9.54 on September 21. However, the stock’s price has since declined on profit-taking. So, let’s find out ...

Broncus Holding, a Hangzhou pulmonary medical device company, completed a $200 million IPO on the Hong Kong exchange that valued the company at nearly $1.3 billion. Suzhou CStone Pharma and US-based EQRx reported their partnered PD-(L)1 antibody increased median progression-free survi...

While Precipio (PRPO) is a lesser-known company in the diagnostics and research industry, it generated significant market buzz in May 2021 when its COVID-19 antibody test became available on Amazon’s (AMZN) platform. However, can the stock continue to advance by relying on the antibody...